Does the size of response to cabozantinib plus nivolumab affect clinical outcomes?
Ongoing results from the phase 3 CheckMate-9ER clinical trial with [...]
Ongoing results from the phase 3 CheckMate-9ER clinical trial with [...]
At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]
This phase 2 clinical trial (ENTRATA) looked at how safe [...]
In this study, the health-related quality of life (HRQoL) of [...]
MEDI0680 and durvalumab are both immunotherapies called checkpoint inhibitors. They [...]
The following presentations from the Educated Patient® Kidney Cancer Summit [...]
At the 2022 European International Kidney Cancer Symposium (EIKCS) in [...]
During 2022 European International Kidney Cancer Symposium (EIKCS) in Antwerp, [...]
A combination therapy with a new targeted therapy (tyrosine kinase [...]
The results from a recent phase 2 trial looked at [...]